

IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

12 March 2019

Imagion Biosystems receives US patent related to treatment of disease

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, has announced that the U.S. Patent and Trademark Office has issued patent #10194825 B2 for “Methods and Apparatuses for the localization and treatment of disease such as cancer”.

The new patent is a continuation-in-part of the company’s core patent which applies to the use of magnetic nanoparticles for the detection of diseases such as cancer. The new patent combines detection with the ability to guide therapy and monitor the effectiveness of treatment, as well as using the nanoparticles themselves for treatment such as by magnetic hyperthermia or as a carrier for chemotherapy or other therapeutic agents. The new patent is the latest in a line of patents, both issued and applications pending, in Australia, Canada, China, EPO, India, Israel, Japan, Russia, and the U.S. The term of the patent extends to 2029.

“This is an important addition to our intellectual property portfolio,” said Bob Proulx, Executive Chairman. “We have long held the view that using our targeted magnetic nanoparticles for detecting cancer was only the first step. There is a much broader opportunity to combine detection with treatment.”

Imagion Biosystems’ current focus on diagnostic imaging addresses a \$2 billion market worldwide. Adding therapeutic utility would expand the revenue opportunity for the company’s nanoparticle technologies to the growing market for hyperthermia-based cancer treatments, as well as cancer therapy markets reported to be as much as \$136 billion. While the overall cancer therapy market is forecast to grow at CAGR 8.37% through 2024, the target-therapy segment, which includes toxin delivery vehicles, is expected to show a higher CAGR of 9.68% in the forecast period. This is driven by growing interest and opportunities in the development of precision medicines such as cancer treatments that target the tumor and spare healthy tissue.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420

Imagion Biosystems Limited

ACN 616 305 027

Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com

For personal use only